Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study

References

• Coronavirus Resource Center of the Johns Hopkins University School of Medicine. Understanding vaccination progress by country 2022 [29 Apr 2022]. Available from: https://coronavirus.jhu.edu/vaccines/international.
   Google Scholar
• HKSAR Government. Latest situation of reported cases of COVID-19 in Hong Kong 2022 [16 Apr 2022]. Available from: http://www.chp.gov.hk/files/misc/latest_situation_of_reported_cases_covid_19_eng.csv.
   Google Scholar
• Li C, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nat Commun. 2021;12(1):1–9.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–350.
   PubMed Web of Science ®Google Scholar
• Patalon T, Saciuk Y, Peretz A, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun. 2022;13(1):1–7.
   PubMed Web of Science ®Google Scholar
• Collie S, Nayager J, Bamford L, et al. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. N Engl J Med. 2022;387(14):1332–1333.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. China’s COVID vaccines have been crucial – now immunity is waning. Nature. 2021 [cited 14 Oct 2021]. Available from: https://www.nature.com/articles/d41586-021-02796-w.
   Google Scholar
• Sauré D, O'Ryan M, Torres JP, et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56–63.
   PubMed Web of Science ®Google Scholar
• Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19.
   PubMed Web of Science ®Google Scholar
• Taylor L. COVID-19: Hong Kong reports world’s highest death rate as zero COVID strategy fails. Br Med J. 2022;376(o420):35177535.
   Google Scholar
• Wan EYF, Chui CSL, Lai FTT, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2021;21:00451–00455.
   Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination. Clin Infect Dis. 2022;75(4):673–681.
   PubMed Web of Science ®Google Scholar
• Li X, Tong X, Yeung WWY, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564–568.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Chui CSL, et al. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):1–8.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Li X, Peng K, et al. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study. Ann Intern Med. 2022;175(3):362–370.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Huang L, Peng K, et al. Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022 Jun;291(6):864–869. doi:10.1111/joim.13453
   PubMed Web of Science ®Google Scholar
• Li X, Tong X, Wong ICK, et al. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022;71(12):2608–2611.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. The Lancet Regional Health – Western Pacific. 2022;21:100393.
   PubMedGoogle Scholar
• Xiong X, Wong CKH, Au ICH, et al. Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022;32(5):505–514.
   PubMed Web of Science ®Google Scholar
• Mesfin Y, Chen D, Bond H, et al. Epidemiology of infections with SARS-CoV-2 Omicron BA. 2 variant in Hong Kong, January–March 2022. medRxiv. 2022.
   Google Scholar
• Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020-march 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495–500.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–222.
   PubMed Web of Science ®Google Scholar
• Miller TE, Garcia Beltran WF, Bard AZ, et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020;34(10):13877–13884.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Groll D, To T, et al. Charlson comorbidity index. Nursing Research (New York). 2013;62(1):2.
   Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–529.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B. 1.1. 529) variant. N Engl J Med. 2022;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION network: test negative, case-control study. Br Med J. 2022;379:e072141.
   PubMedGoogle Scholar
• Gram MA, Emborg H-D, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the alpha, delta, or omicron SARS-CoV-2 variant: a nationwide Danish Cohort Study. PLoS Med. 2022;19(9):e1003992.
   PubMed Web of Science ®Google Scholar
• Can G, Acar HC, Aydin SN, et al. Waning effectiveness of CoronaVac in real life: a retrospective cohort study in health care workers. Vaccine. 2022;40(18):2574–2579.
   PubMed Web of Science ®Google Scholar
• Suah JL, Husin M, Tok PSK, et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study. Int J Infect Dis. 2022;119:69–76.
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhou R, Wang Y, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904.
   PubMed Web of Science ®Google Scholar
• Govender M, Hopkins FR, Göransson R, et al. T cell perturbations persist for at least 6 months following hospitalization for COVID-19. Front Immunol. 2022;13:931039.
   PubMed Web of Science ®Google Scholar
• Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398(10308):1377–1380.
   PubMed Web of Science ®Google Scholar
• Cevik M, Grubaugh ND, Iwasaki A, et al. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell. 2021;184(20):5077–5081.
   PubMed Web of Science ®Google Scholar
• Deng Y, Li Y, Yang R, et al. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol Immunol. 2021;18(8):2040–2041.
   PubMed Web of Science ®Google Scholar
• Vályi-Nagy I, Matula Z, Gönczi M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience. 2021;43(5):2321–2331.
   PubMed Web of Science ®Google Scholar